Akt Inhibitors MK-2206 and Nelfinavir overcome mTOR inhibitor resistance in DLBCL

PURPOSE: The mTOR (mammalian Target of Rapamycin) pathway is constitutively activated in Diffuse Large B-Cell Lymphoma (DLBCL). mTOR inhibitors (mTORi) have activity in DLBCL, although response rates remain low. We evaluated DLBCL cell lines with differential resistance to the mTORi Rapamycin, in or...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Petrich, Adam, Leshchenko, Violetta, Kuo, Pei-Yu, Xia, Bing, Thirukonda, Venu K., Ulahannan, Netha, Gordon, Shanisha, Fazzari, Melissa J., Ye, B. Hilda, Sparano, Joseph, Parekh, Samir
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2012
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3889476/
https://ncbi.nlm.nih.gov/pubmed/22338016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1407
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items